Mann mit Smartphone und Tablet (Symbolbild).
Mittwoch, 12.01.2022 07:30 von | Aufrufe: 156

InMode Expects Record Fourth Quarter & Full Year 2021 Financial Results, Q4 Revenue Between $109.5M-$110M

Mann mit Smartphone und Tablet (Symbolbild). © metamorworks / iStock / Getty Images Plus / Getty Images

PR Newswire

YOKNEAM, Israel, Jan. 12, 2022 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2021 before the Nasdaq market opens on Thursday, February 10, 2022. 

InMode Logo (PRNewsfoto/InMode)

InMode is currently finalizing its financial results for the fourth quarter and full year of 2021. While complete financial information and operating data are not yet available, set forth below are certain preliminary financial results for said period, subject to final adjustments and other developments that may arise between now and the time such financial results are published. Based on preliminary results, management expects:

  • Record revenue for the fourth quarter in the range of $109.5M-$110M and revenue for the full year of 2021 in the range of $356.5M-$357M, higher than previously announced guidance of $343M-$347M
  • Record Non-GAAP1 earnings per diluted share for the fourth quarter and full year of 2021 in the range of $0.61 and $0.62 and $2.02 to $2.03, respectively
  • Non-GAAP1 gross margin for the full year of 2021 in the range of 84-86%
  • Full year 2022 revenue in the range of $415M-$425M

"Our record results in the fourth quarter and in 2021 reflect the growing global demand for our products. We are especially encouraged by the consistently increased sales of consumables. This is the best indication that demand for our procedures keeps growing," commented Moshe Mizrahy, InMode's CEO.

InMode will host a conference call to discuss the fourth quarter and full year of 2021 financial results on February 10, at 8:30 a.m. Eastern Time Management members on the call will include Moshe Mizrahy, Chairman and Chief Executive Officer; Yair Malca, Chief Financial Officer; Dr. Michael Kreindel, Chief Technology Officer; Shakil Lakhani, President of North America; and Dr. Spero Theodorou, Chief Medical Officer.

The Company encourages participants to pre-register for the conference call using the following linkhttps://dpregister.com/sreg/10162779/f0769e8c28. Callers will receive a unique dial-in number upon registration, which enables immediate access on the day of the call.

Participants may pre-register at any time, including up to and after the call start time.

For callers that opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number.


ARIVA.DE Börsen-Geflüster

Kurse

16,3375
0,00%
Inmode Realtime-Chart

[1] Please refer to "Use of Non-GAAP Financial Measure" below for important information about non-GAAP financial measures. Non-GAAP financial results exclude stock-based compensation and related tax adjustments.

U.S. Toll-Free: 1-833-316-0562
Israel Toll-Free: 1-80-9212373
International: 1-412-317-5736

At:

8:30 a.m. Eastern Time
5:30 a.m. Pacific Time
3:30 p.m. Israel Time

The conference call will also be webcast live from a link on InMode's website at https://inmodemd.com/investors/events-presentations/. A replay of the conference call will be available until February 24, 2022. To access the replay, please dial one of the following numbers:

Replay U.S. TOLL-FREE: 1-877-344-7529
Replay Canada TOLL-FREE: 1-855-669-9658
Replay TOLL/INTERNATIONAL: 1-412-317-0088
Replay Pin Number: 4618253

A replay will also be available for 90 days on InMode's website at: https://inmodemd.com/investors/events-presentations/

About InMode 
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures and markets devices harnessing novel radio-frequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology and ophthalmology. For more information about InMode, please visit www.inmodemd.com.

Use of Non-GAAP Financial Measure  
This release includes an estimate of InMode's expected non-GAAP earnings per diluted share for the fourth quarter and full year of 2021. Because this financial measure is used in InMode's internal analysis of financial and operating performance, management believes that it provides greater transparency to investors of management's view of InMode's economic performance. Management also believes the presentation of this measure allows investors to more effectively evaluate and compare the performance of InMode to that of its peers, although InMode's presentation of this non-GAAP measure may not be comparable to other similarly titled measures of other companies. InMode has not provided a reconciliation of non-GAAP earnings per diluted share to the corresponding GAAP financial measure on a forward-looking basis due to the potential variability, limited visibility and unpredictability. See "Forward-Looking Statements" for additional information.

Forward-Looking Statements    
This press release contains certain forward-looking statements. Words such as "expects" and "strives" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of InMode, including, without limitation, risks relating to the impact of the COVID-19 outbreak and the risk factors and other matters set forth in its Annual Report on Form F-20 for the year ended December 31, 2020 filed with the Securities and Exchange Commission on February 10, 2021. The COVID-19 outbreak has caused significant volatility and disruption in the financial markets both globally and in the United States. If COVID-19 continues to spread or the response to contain it is unsuccessful, InMode could experience material adverse effects on its business, financial condition, liquidity and results of operations. InMode undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Company Contact:

Yair Malca

Chief Financial Officer

Phone: (949) 305-0108

Email: Yair.Malca@inmodemd.com

Investor Relations Contact:

Miri Segal

MS-IR LLC

Phone: (917) 607-8654

Email: ir@inmodemd.com

 

Cision View original content:https://www.prnewswire.com/news-releases/inmode-expects-record-fourth-quarter--full-year-2021-financial-results-q4-revenue-between-109-5m-110m-301458964.html

SOURCE InMode Ltd.

Werbung

Mehr Nachrichten zur Inmode Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Andere Nutzer interessierten sich auch für folgende News